Paper Review Records
All Paper Review Records
13 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
169
days
Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR -altered non-small-cell lung cancer
AuthorsNatasha B. Leighl; Antonio Passaro; Hiroaki Akamatsu; Alexander I. Spira; Danny Nguyen; Angel Qin; Julia Schuchard; Mohamed Gamil; Mahadi Baig; Mariam Alexander
Affiliations1. aPrincess Margaret Cancer Centre, Toronto, ON, Canada; 2. bDivision of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy; 3. cInternal Medicine III, Wakayama Medical University, Wakayama, Japan; 4. dVirginia Cancer Specialists, Fairfax, VA, USA; 5. eCity of Hope National Medical Center, Duarte, CA, USA; 6. fUniversity of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; 7. gJohnson & Johnson, Horsham, PA, USA; 8. hJohnson & Johnson, Spring House, PA, USA; 9. iJohnson & Johnson, Raritan, NJ, USA; 10. jHollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
62
days
Cancer control after pausing treatment with larotrectinib in responding children with sarcoma and a TRK fusion: a plain language summary
AuthorsLeo Mascarenhas; Christopher Ollis; Yuvraj Singh; Linet Menachery; Domnita-Ileana Burcoveanu; Esther De La Cuesta; Cornelis M van Tilburg; Theodore W Laetsch
Affiliations1. aGuerin Children’s and Cedars-Sinai Cancer, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA; 2. bPatient author; 3. cValley Springs, CA, USA; 4. dCaregiver author, Gurugram, Haryana, India; 5. eCaregiver author, White Plains, NY, USA; 6. fBayer HealthCare Pharmaceuticals, Inc, Basel, Switzerland; 7. gBayer HealthCare Pharmaceuticals, Inc, Whippany, NJ, USA; 8. hHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; 9. iClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany; 10. jHeidelberg University, Heidelberg Faculty of Medicine, Department of Pediatric Oncology, Hematology, Immunology, and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany; 11. kNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany; 12. lChildren’s Hospital of Philadelphia / University of Pennsylvania, Philadelphia, PA, USA
163
days
Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors
AuthorsMenghua Xia; Weifu Lv; Wei Zhao; Liqin Bi; Xueran Guo; Mengxia Zhang; Liangping Shi
Affiliations1. The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China
183
days
Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences
AuthorsMatthew Quaife; Cecilia Jimenez-Moreno; Blanca Gros Otero; Aisha Asra; Niodita Gupta-Werner; Katharine S. Gries; Marie-Kristin Leisten; Kathryn Matt; Robin Carson; Robyn Dennis; Jianming He; Bennett Levitan; Sacheeta Bathija
Affiliations1. Evidera; 2. Johnson & Johnson
196
days
Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study
AuthorsShan Xu; Hao Yang; Nan Hu
Affiliations1. The Third Affiliated Hospital of Nanjing Medical University; 2. The Third Affiliated Hospital of Soochow University
239
days
A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing
Authorsİmdat Eroğlu; Sıla Soylu Koçoğlu; Eron Merovci; Gözde Savaş; Fatih Gürler; Osman Sutcuoglu; Ugur Coskun; Aytug Uner; Murat Ucar; Burak Karaarslan; Ahmet Özet; Nuriye Özdemir; Ozan Yazıcı
Affiliations1. Gazi University School of Medicine
125
days
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10
AuthorsHope S. Rugo; Peter Schmid; Javier Cortes; Toshimi Takano; Peter A. Fasching; Yeon Hee Park; Giampaolo Bianchini; Sandra Ximena Franco; Cynthia Villarreal-Garza; Olivier Tredan; Yongmei Yin; Romualdo Barroso-Sousa; Xuan Peng; Usha Malhotra; Karen Lisa Smith; Aditya Bardia
Affiliations1. City of Hope Comprehensive Cancer Center; 2. Queen Mary University of London; 3. Quiron Group; 4. Cancer Institute Hospital of Japanese Foundation for Cancer Research; 5. University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg; 6. Sungkyunkwan University School of Medicine; 7. IRCCS Ospedale; 8. Vita-Salute San Raffaele University; 9. Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo; 10. Breast Cancer Center Hospital Zambrano Hellion TecSalud; 11. Centre Léon Bérard and Cancer Research Center of Lyon; 12. The First Affiliated Hospital of Nanjing Medical University; 13. Brasilia Hospital; 14. Inc; 15. University of California Los Angeles, Jonsson Comprehensive Cancer Center
83
days
Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience
AuthorsRiddhi A. Babel; Stephen V. Liu; Tao Fan; Mayur M. Amonkar; Vamsidhar Velcheti
Affiliations1. Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA; 2. Georgetown University; 3. Mayo Clinic
101
days
Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States
AuthorsJennifer R. Brown; Talha Munir; Andrew H. Lipsky; Swetha Challagulla; David Campbell; Keri Yang; Qianhong Fu; Wassim Aldairy; Rhys Williams; Constantine S. Tam
Affiliations1. Dana-Farber Cancer Institute and Harvard Medical School; 2. Leeds Teaching Hospitals NHS Trust; 3. Columbia University Medical Center; 4. BeOne Medicines Ltd., San Carlos, CA, USA; 5. Curta Inc., Seattle, WA, USA; 6. Alfred Hospital and Monash University
226
days
Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries
AuthorsHarshali Patel; Lynn Huynh; Patrick Squires; Jennifer Prescott; Katherine Ryland; Maryaline Catillon; Tracy Guo; Kelvin Tamakloe; Steven Liu; Mei Sheng Duh; Monika Raut; Craig A. Portell
Affiliations1. Merck & Co., Inc; 2. Analysis Group, Inc; 3. University of Virginia School of Medicine
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days